Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

18028 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-22

Study Completion Date

2021-02-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Replication of the VERO Osteoporosis Trial in Healthcare Claims Data

NCT04879420

Osteoporosis

COMPLETED

Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)

NCT00145327

Osteoporosis

COMPLETED PHASE3

HORIZON-PFT: Pivotal Fracture Trial

NCT00049829

Osteoporosis

COMPLETED PHASE3

Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis

NCT00670319

Osteoporosis, Postmenopausal

COMPLETED PHASE3

Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

NCT00431444

Osteoporosis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as is possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates according to standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Raloxifene

Reference Group

Raloxifene

Intervention Type DRUG

Raloxifene dispensing claim is used as the reference group.

Zoledronic Acid

Exposure Group

Zoledronic Acid

Intervention Type DRUG

Zoledronic Acid dispensing claim is used as the exposure group.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Raloxifene

Raloxifene dispensing claim is used as the reference group.

Intervention Type DRUG

Zoledronic Acid

Zoledronic Acid dispensing claim is used as the exposure group.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Zoledronic acid indication for treatment of postmenopausal women with osteoporosis was approved by FDA on Aug 20, 2007.

* For IBM MarketScan: Aug 21, 2007 - December 31, 2018 (end of available data)
* For Optum CDM: Aug 21, 2007 - Mar 31, 2020 (end of available data)

* Postmenopausal women between the ages of 65 and 89 years
* Osteoporosis diagnosis

Exclusion Criteria

* Bisphosphonate users
* Previous use of:

1. Any use of parathyroid hormone
2. Use of anabolic steroids or growth hormone within 6 months before cohort entry date OR
3. Use of oral or intravenous systemic corticosteroids within 12 months of cohort entry date
* Serious disease that may limit life expectancy to less than 6 months
* Malignant neoplasm diagnosis within 12 months prior to the cohort entry date
* Conditions that influence bone metabolism
* Treatment and Prevention of Glucocorticoid-Induced Osteoporosis
* Treatment of Paget's Disease of Bone
* Alcohol abuse/dependence OR Drug abuse/dependence OR Non-compliance
* Pregnancy
* Diagnosis and procedure for amputee of lower limb
* Use of Zoledronic acid within 450 days prior to the cohort entry date
* Use of Denosumab within 450 days prior to the cohort entry date
* Diagnosis of End-Stage Renal Disease OR Diagnosis and procedure for Kidney transplant
* Diagnosis of End-Stage Liver Disease: Cirrhosis, Hepatic decompensation
* Blindness or compromised vision
* Use of Abaloparatide within 450 days prior to the cohort entry date
* Use of Romosozumab within 450 days prior to the cohort entry date

Minimum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No